Genentech Sues University of Pennsylvania Over Patent

The pursuit of effective cancer treatments is not only fraught with scientific complexities, but also legal complications. Biotech company Genentech is suing Penn for patent fraud on a cancer treatment that both entities believe to be theirs. At Penn, the treatment was tested on transgenic mice who were engineered to have cancer. When a patent from biotech company Genentech came to Penn’s attention, they claimed Genentech was infringing on their patent. Genentech filed a complaint in May 2010 and is now suing for patent fraud.